肿瘤坏死因子相关凋亡诱导配体(TRAIL)检测试剂盒(化学发光免疫分析法)
CLIA Kit for Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL)
CD253; TNFSF10; APO2L; Apo2-L; TL2; TRAIL; Tumor Necrosis Factor Ligand Superfamily Member 10; Apo-2 Ligand
- 编号SCA139Hu
- 物种Homo sapiens (Human,人)相同的名称,不同的物种。
- 实验方法双抗夹心
- 反应时长2h, 40min
- 检测范围41.2-30,000pg/mL
- 灵敏度最小可检测剂量小于等于15.5pg/mL.
- 样本类型Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下载英文说明书 中文说明书
- 规格48T96T96T*596T*1096T*100
- 价格¥ 3528¥ 5040¥ 22680¥ 42840¥ 352800
- 欲了解实际交易价格和更多情况,请与当地经销商联系!
特异性
                        本试剂盒用于检测肿瘤坏死因子相关凋亡诱导配体(TRAIL),经检测与其它相似物质无明显交叉反应。
                        由于受到技术及样本来源的限制,不可能完成对所有相关或相似物质交叉反应检测,因此本试剂盒有可能与未经检测的其它物质有交叉反应。
                    
回收率
分别于定值血清及血浆样本中加入一定量的肿瘤坏死因子相关凋亡诱导配体(TRAIL)(加标样品),重复测定并计算其均值,回收率为测定值与理论值的比率。
| 样本 | 回收率范围(%) | 平均回收率(%) | 
| serum(n=5) | 93-101 | 96 | 
| EDTA plasma(n=5) | 98-105 | 101 | 
| heparin plasma(n=5) | 93-101 | 96 | 
精密度
                    精密度用样品测定值的变异系数CV表示。CV(%) = SD/mean×100 
                    批内差:取同批次试剂盒对低、中、高值定值样本进行定量检测,每份样本连续测定20 次,分别计算不同浓度样本的平均值及SD值。
                    批间差:选取3个不同批次的试剂盒分别对低、中、高值定值样本进行定量测定,每个样本使用同一试剂盒重复测定8次,分别计算不同浓度样本的平均值及SD值。
                    批内差: CV<10% 
                    批间差: CV<12% 
线性
在定值血清及血浆样本内加入适量的肿瘤坏死因子相关凋亡诱导配体(TRAIL),并倍比稀释成1:2,1:4,1:8,1:16的待测样本,线性范围即为稀释后样本中肿瘤坏死因子相关凋亡诱导配体(TRAIL)含量的测定值与理论值的比率。
| 样本 | 1:2 | 1:4 | 1:8 | 1:16 | 
| serum(n=5) | 99-105% | 78-104% | 84-94% | 90-101% | 
| EDTA plasma(n=5) | 91-105% | 96-104% | 98-105% | 93-103% | 
| heparin plasma(n=5) | 97-105% | 96-103% | 89-103% | 86-103% | 
稳定性
                    经测定,试剂盒在有效期内按推荐温度保存,其活性降低率小于5%。
                    为减小外部因素对试剂盒破坏前后检测值的影响,实验室的环境条件需尽量保持一致,尤其是实验室内温度、湿度及温育条件。其次由同一实验员来进行操作可减少人为误差。
                
实验流程
1. 实验前标准品、试剂及样本的准备;
                            2. 加样(标准品及样本)100µL,37°C孵育1小时;
                            3. 吸弃,加检测溶液A100μL,37°C孵育1小时;
                            4. 洗板3次;
                            5. 加检测溶液B100µL,37°C孵育30分钟;
                            6. 洗板5次;
                            7. 加底物100µL,37°C孵育10分钟;
                            8. 读数。
实验原理
将肿瘤坏死因子相关凋亡诱导配体(TRAIL)抗体包被于96孔微孔板中,制成固相载体,向微孔中分别加入标准品或标本,其中的肿瘤坏死因子相关凋亡诱导配体(TRAIL)与连接于固相载体上的抗体结合,然后加入生物素化的肿瘤坏死因子相关凋亡诱导配体(TRAIL)抗体,将未结合的生物素化抗体洗净后,加入HRP标记的亲和素,再次彻底洗涤后加入底物。加入底物后会产生辉光型光信号。发射光强度和样品中的肿瘤坏死因子相关凋亡诱导配体(TRAIL)呈正相关。用化学发光仪测定相对光单位(RLU),计算样品浓度。
增值服务
相关产品
| 编号 | 适用物种:Homo sapiens (Human,人) | 应用(仅供研究使用,不用于临床诊断!) | 
| RPA139Hu01 | 肿瘤坏死因子相关凋亡诱导配体(TRAIL)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. | 
| RPA139Hu02 | 肿瘤坏死因子相关凋亡诱导配体(TRAIL)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. | 
| APA139Hu01 | 肿瘤坏死因子相关凋亡诱导配体(TRAIL)活性蛋白 | Cell culture; Activity Assays. | 
| PAA139Hu01 | 肿瘤坏死因子相关凋亡诱导配体(TRAIL)多克隆抗体 | WB; IHC; ICC; IP. | 
| PAA139Hu02 | 肿瘤坏死因子相关凋亡诱导配体(TRAIL)多克隆抗体 | WB; IHC; ICC; IP. | 
| LAA139Hu71 | 肿瘤坏死因子相关凋亡诱导配体(TRAIL)多克隆抗体(生物素标记) | WB; IHC; ICC. | 
| LAA139Hu81 | 肿瘤坏死因子相关凋亡诱导配体(TRAIL)多克隆抗体(异硫氰酸荧光素标记) | WB; IHC; ICC; IF. | 
| MAA139Hu25 | 肿瘤坏死因子相关凋亡诱导配体(TRAIL)单克隆抗体 | WB; IHC; ICC; IP. | 
| MAA139Hu24 | 肿瘤坏死因子相关凋亡诱导配体(TRAIL)单克隆抗体 | WB; IHC; ICC; IP. | 
| MAA139Hu22 | 肿瘤坏死因子相关凋亡诱导配体(TRAIL)单克隆抗体 | WB | 
| MAA139Hu21 | 肿瘤坏死因子相关凋亡诱导配体(TRAIL)单克隆抗体 | WB | 
| MAA139Hu23 | 肿瘤坏死因子相关凋亡诱导配体(TRAIL)单克隆抗体 | WB; ICC/IF | 
| LAA139Hu72 | 肿瘤坏死因子相关凋亡诱导配体(TRAIL)单克隆抗体(生物素标记) | WB | 
| LAA139Hu82 | 肿瘤坏死因子相关凋亡诱导配体(TRAIL)单克隆抗体(异硫氰酸荧光素标记) | WB; IHC; ICC; IF. | 
| SEA139Hu | 肿瘤坏死因子相关凋亡诱导配体(TRAIL)检测试剂盒(酶联免疫吸附试验法) | Enzyme-linked immunosorbent assay for Antigen Detection. | 
| SCA139Hu | 肿瘤坏死因子相关凋亡诱导配体(TRAIL)检测试剂盒(化学发光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. | 
| LMA139Hu | 肿瘤坏死因子相关凋亡诱导配体(TRAIL)等多因子检测试剂盒(流式荧光发光法) | FLIA Kit for Antigen Detection. | 
| KSA139Hu01 | 肿瘤坏死因子相关凋亡诱导配体(TRAIL)检测试剂盒DIY材料(酶联免疫吸附试验法) | Main materials for "Do It (ELISA Kit) Yourself". | 
参考文献
| 杂志 | 参考文献 | 
| PLOS ONE | Intranasal Administration of Recombinant TRAIL Down-Regulates CXCL-1/KC in an Ovalbumin-Induced Airway Inflammation Murine Model[Pubmed:25506835] | 
| PLOS ONE | Soluble TRAIL Concentration in Serum Is Elevated in People with Hypercholesterolemia[PubMed: 26633016] | 
| Scientific Reports | Non-alcoholic fatty liver disease, vascular inflammation and insulin resistance are exacerbated by TRAIL deletion in mice[pubmed:28507343] | 
| Journal of Molecular Medicine | TRAIL and TRAIL Receptors as Prognostic Markers in Breast Cancer Patients[Pubmed: 31183506] | 
| life sciences | Nifuroxazide attenuates experimentally-induced hepatic encephalopathy and the associated hyperammonemia and cJNk/caspase-8/TRAIL activation in rats[Pubmed: 32259601] | 
| Int Immunopharmacol | Cardio-protective impact of gabapentin against doxorubicin-induced myocardial toxicity in rats; emphasis on modulation of inflammatory-apoptotic signaling[Pubmed: 33199237] | 
| ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY | Chemo-preventive effect of crocin against experimentally-induced hepatocarcinogenesis via regulation of apoptotic and Nrf2 signaling pathways[Pubmed: 32942000] | 
| J Biochem Mol Toxicol | Tranilast abrogates cisplatin©\induced testicular and epididymal injuries: An insight into its modulatory impact on apoptosis/proliferation[34047436] | 




